Patients
PDAC
ONCOLOGY, METASTASES
We enrolled patients with an Eastern Cooperative Oncology Group performance status of 0–1 with single, radiographically suspicious, surgically resectable PDACs, no distant metastases and ≥5 neoantigens. We excluded patients with metastatic, borderline or locally unresectable PDACs, and patients who received neoadjuvant therapy.After surgery, we included patients with pathologically confirmed PDAC with R0/R1 margins. Additional eligibility criteria and ethical study conduct information are in the protocol (Supplementary Data 